|
Mar 13
|
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
|
|
Mar 12
|
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
|
|
Mar 10
|
Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Feb 26
|
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
|
|
Feb 26
|
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Feb 23
|
Dr. Gregory George MD PhD Joins Mesoblast Board
|
|
Feb 19
|
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
Exploring 3 High Growth Tech Stocks In Australia
|
|
Nov 8
|
ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth
|
|
Nov 6
|
Three High Growth Tech Stocks in Australia
|
|
Oct 4
|
ASX Growth Companies With High Insider Ownership In October 2024
|
|
Oct 3
|
ASX Growth Companies With High Insider Ownership October 2024
|
|
Oct 2
|
3 High Growth ASX Stocks With Significant Insider Ownership
|
|
Oct 1
|
Top High Growth Tech Stocks To Watch In Australia October 2024
|
|
Sep 30
|
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
|
|
Jul 31
|
Mesoblast Insiders Land Bargain With Gains Of US$58m
|
|
Jul 31
|
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
|
|
Jul 23
|
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
|
|
Jul 23
|
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
|